The retinoblastoma (Rb) gene product is a tumor suppressor that is mutated or inactivated in many types of human cancers. Although Rb is known to be an upstream negative regulator of Abl protein tyrosine kinase, we propose here that Rb also functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive chronic myelogenous leukemia (CML). We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the Cterminal domain of the molecule. We also show that ectopic expression of Rb induces apoptosis in Abldependent tumor cells by inhibiting the Abl tyrosine kinase activity, and that Rb-induced apoptosis is compromised by Abl-catalysed phosphorylation of Rb at Y805. Furthermore, the silencing of endogenous Rb by RNA interference induced apoptosis in Abl-dependent tumor cells. Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML.
Introduction
The retinoblastoma (Rb) gene product is a tumor suppressor that regulates multiple cellular processes such as growth, differentiation, cell fate specification, and apoptosis, and is mutated or inactivated in many types of human cancers (Horowitz et al., 1989; Onadim et al., 1992; Weinberg, 1995; Sherr, 1996; Harbour and Dean, 2000; Zhang et al., 2004) . The tumor suppressor activity of Rb derives from its ability to inhibit cell cycle transit by repressing the transcription of genes required for the G1-S-phase transition, such as E2F/Dp1-dependent transcription (Nevins, 1992; Helin et al., 1993; Sellers et al., 1995; Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) . Rb also regulates apoptosis and is cleaved by caspases in apoptotic cells (Janicke et al., 1996; Tan and Wang, 1998; Harbour and Dean, 2000) . Expression of caspase-resistant Rb in mice yields cell-type and signal-dependent protection from apoptosis (Harbour and Dean, 2000; Chau et al., 2002) . In contrast, it has also been reported that restoration of Rb expression in Rb-negative prostate cancer cells sensitizes the cells to apoptosis induced by g-irradiation (Bowen et al., 2002) , and phosphorylation of Rb at S567 triggers apoptosis (Ma et al., 2003) . The reason for these apparent contradictory observations regarding the role of Rb in tumor cell apoptosis is unknown, but it has been postulated that Rb function might depend on the tumor cell type and its regulation by site-specific modification, such as phosphorylation (Tan and Wang, 1998; Harbour and Dean, 2000; Ma et al., 2003) .
The nonreceptor tyrosine kinase Abl resembles Src family kinases, but has unique features, including the ability to shuttle between the cytoplasmic and nuclear compartments (Baltimore et al., 1995; Wen et al., 1996; Taagepera et al., 1998; Wang, 2000) . Activation of Abl by DNA damage can induce apoptosis in the nucleus (Baskaran et al., 1997; Shafman et al., 1997; Wang, 2000) . In contrast, Abl also has oncogenic potential that is activated in the Bcr/Abl hybrid protein of chronic myelogenous leukemia (CML). The specific inhibitor of Abl, imatinib, has been proved to be a useful therapeutic agent for Bcr/Abl-positive CML (Druker et al., 2001; Calabretta and Perrotti, 2004; Harata et al., 2004) . Bcr/ Abl activates a number of cytoplasmic signal transduction pathways that are normally controlled by receptor tyrosine kinases (Druker et al., 2001) , while the downstream effectors of Bcr/Abl are not well understood. The C-terminal domain of Rb binds the kinase domain of Abl and inhibits its catalytic activity (Guo et al., 1999; Wang, 2000) , and thus Rb is considered to be an upstream negative regulator of Abl. However, the physiological link between Rb and Abl in cancer cells still remains obscure.
Here, we demonstrate that Rb functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive CML. Based on these data, we propose that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells.
Results

Constitutive tyrosine phosphorylation of Rb in tumor cells
Treatment with genistein, an inhibitor of protein tyrosine kinases, induced apoptosis in HeLa S3 cells (data not shown), suggesting that constitutive tyrosine phosphorylation is necessary for survival of HeLa S3 cells. To gain more insight into this observation, we prepared a fraction containing tyrosine-phosphorylated proteins from HeLa S3 cell extracts by affinity-capture with an antibody to phosphotyrosine (Figure 1a , upper panel). The tumor suppressor protein, Rb, was one of many proteins found in the fraction that was potentially phosphorylated at tyrosine within the cells (lower panel). Interestingly, we found that Rb was tyrosinephosphorylated in certain cell types including Bcr/Ablpositive CML cell lines such as KU-812 and K562, whereas other human tumor cell lines, including MCF-7, A549, and 293-T cells, did not contain the tyrosinephosphorylated form of Rb (Figure 1b) . HeLa S3 is not typical from this viewpoint, as the cell expresses wildtype Abl instead of Bcr/Abl; however, Abl activity appears to be essential for this cell because imatinib, a specific inhibitor of Abl, induced apoptosis ( Figure 2) . Thus, we postulated that Rb might be constitutively phosphorylated at tyrosine in Abl-dependent tumor cells.
Tyrosine phosphorylation of Rb by Abl tyrosine kinase
It has been reported that Rb is an upstream negative regulator of Abl tyrosine kinase (Guo et al., 1999; Wang, 2000) . To explore whether Rb is a substrate of Abl and serves as a downstream effector of Abl, Nterminal (Rb-N), A/B pocket (Rb-A/B), and C-terminal (Rb-C) domains of Rb were expressed in bacteria with a GST tag and subjected to an in vitro kinase assay. Of the three segments, only Rb-C was strongly phosphorylated with a constitutively active (W118K), but not an inactive (kinase dead (KD)), mutant of Abl (Supplementary Figure 1a and b) . To identify the phosphorylation sites, Rb-C was incubated with or without Abl and subjected to mass spectrometry (MS) analysis. A doubly charged peptide ion (m/z ¼ 676.25) was only detected after Rb-C was incubated with Abl ( Figure 3a , lower panel, indicated by an arrow). This ion was assigned to the peptide fragment spanning Rb residues 799-810 having the sequence IPGGNIpYISPLK, including phosphorylated Y805 (Figure 3b, lower panel) . We found the equivalent unphosphorylated peptide fragment (m/z ¼ 636.22) in the Rb-C samples incubated with and without Abl (Figure 3a and b, indicated by arrowheads). Although we detected an additional, minor phosphopeptide spanning Rb residues 768-787, which was probably phosphorylated at Y771 (Supplementary Figure 2c) , Abl-catalysed tyrosine phosphorylation of Rb K Nagano et al only the Rb-C phosphopeptide fragment surrounding Y805 has a sequence that adheres to a consensus sequence motif for Abl-catalysed phosphorylation (I/L/V-Y-X 1-5 -P/F), as determined in a previous study (Figure 3c ) (Cujec et al., 2002) .
In vitro kinase assays with [g-32 P]ATP also demonstrated that Rb-C was phosphorylated via Abl, and the reaction was reversed by treatment with alkaline phosphatase (Figure 4a and data not shown). Studies using a series of point mutants of tyrosine residues within Rb-C showed that the Abl-catalysed phosphorylation reaction was significantly reduced in a Y805F mutant and was completely blocked in a Y771F/Y805F double mutant (Figure 4a ). Thus, Abl phosphorylates Rb primarily at Y805 and partially at Y771.
Full-length Rb was phosphorylated in vivo by the Abl W118K mutant coexpressed in 293-T cells (Figure 4b ), while the phosphorylation did not occur with the dominant-negative KD mutant (data not shown). To determine the sites of phosphorylation catalysed by the W118K mutant of Abl in vivo, we constructed Flagtagged point mutants of Rb, in which Y771 or Y805 was replaced by phenylalanine. The Abl W118K mutant phosphorylated both wild-type Rb and the Y771F mutant to the same level, but phosphorylated the Y805F mutant much less efficiently even though the enzyme bound equally to the Rb mutants ( Figure 4b ). These results demonstrate that Abl phosphorylates Rb predominantly at Y805 both in vivo and in vitro, and suggest that Rb may be a downstream effector of Abl.
To further examine whether Rb was phosphorylated at Y805 endogenously within the cell, the phospho-Rb (Y805)-specific rabbit polyclonal antibody was raised against a synthetic phosphopeptide antigen including phosphoY805 (Materials and methods). The resulting antibody recognized Rb-C only when the protein was incubated with the constitutive active W118K mutant of Abl (Figure 5a ). It also recognized the wild-type Rb and the Y771F mutant, but failed to detect the Y805F mutant, when the proteins were coexpressed with Figure 2 HeLa S3 is sensitive to a specific inhibitor of Abl, imatinib. HeLa S3 cells were treated with imatinib (1 mM), stained with Hoechst 33342 (2 mg/ml), and subjected to TUNEL assay at the indicated time points.
Abl-catalysed tyrosine phosphorylation of Rb K Nagano et al W118K in 293-T cells (Figure 5b ), indicating that it was specific to the Y805-phosphorylated form of Rb. This antibody recognized endogenous Rb in K562 cells (Figure 5c ), indicating that the protein carried a phosphorylated Y805. However, Rb became undetectable by the antibody after the cells were treated with imatinib, a potent inhibitor of Bcr/Abl, for 24 h (Figure 5c ), whereas the activity of Bcr/Abl was completely inhibited (Figure 5d ). Taken together, our results suggest that Bcr/Abl phosphorylates Rb at Y805 endogenously within K562 cells.
Ectopic expression of Rb induces apoptosis in tumor cells compromised by Abl-catalysed phosphorylation at Y805
It is known that the tyrosine kinase activity of Abl can be assessed by the extent of autophosphorylation. In fact, the W118K mutant of Abl was heavily phosphorylated when the mutant was expressed in the cell (Figure 4c ). However, we noted that the W118K mutant recovered by coimmunoprecipitation with Rb was not detectable by the anti-phosphotyrosine antibody (Figure 4b ), suggesting that Rb inhibited the kinase activity of Abl. Likewise, the tyrosine kinase activity of Abl appeared to be reduced significantly when the kinase was recovered from the cells that were coexpressed with Rb or its Y805F mutant (Figure 4c ). Thus, our results suggest that excess Rb, as well as its Y805F mutant, binds and inhibits Abl tyrosine kinase activity.
Given that excess Rb inhibits Abl tyrosine kinase activity, we investigated the possible involvement of Rb in apoptosis of Abl-dependent tumor cells. Ectopic expression of GFP-tagged Rb induced the release of cytochrome c from mitochondria to the cytoplasm, condensation of nuclei, and DNA fragmentation in more than 50% of HeLa S3 cells (Figure 6a ). Overexpression of Rb without GFP tag also induced apoptosis (data not shown). The Rb-induced apoptosis was also observed in the Abl-dependent CML cell lines (KU-812 and K562), but not in other tumor cell lines (MCF-7, A549, and 293-T cells; Figure 6b ), suggesting that Rb induced apoptosis by inhibiting Abl tyrosine kinase activity. Consistent to this hypothesis, we found that coexpression of the constitutively active Abl W118K mutant could rescue cells from Rb-induced apoptosis, whereas the nonfunctional KD mutant had no effect (Figure 7a) .
To examine the significance of Y805 phosphorylation in Rb-induced apoptosis, we prepared Y805F and Y805D Rb mutants in which the tyrosine residue was substituted by the neutral amino acid, phenylalanine, or by the acidic amino acid, aspartic acid, respectively, to mimic nonphosphorylated and phosphorylated forms of Rb. Ectopic expression of Y805F induced apoptosis at a level similar to wild-type Rb in HeLa S3 cells (Figure 7b) . However, the Y805F-induced apoptosis was only partially suppressed by coexpression with W118K ( Figure 7a and c, compare between Rb þ W118K and Y805F þ W118K). In contrast, the Y771F-induced apoptosis was suppressed by W118K at a level similar to wild-type Rb (Supplementary Figure 2) . In addition, the apoptotic rate was partially suppressed when the Y805D mutant that mimicked a phosphorylated form of Rb was overexpressed within the cell, whereas Y771D was not effective (Figure 7b , c, and Supplementary Figure 2) . Thus, our results suggest that Abl-catalysed phosphorylation of Rb at Y805 is necessary, but not sufficient, for survival of certain tumor cell types, including Bcr/Abl-positive CML.
Silencing of endogenous Rb by RNA interference (RNAi) induced apoptosis in Abl-dependent tumor cells To further assess the involvement of Rb in survival of Abl-dependent human tumor cells, we prepared diced short interfering RNA (siRNA) of Rb and examined the effect of Rb silencing on the cells. Of three constructs designated as si-Rb-N, si-Rb-AB, and si-Rb-C (Materials and methods), si-Rb-N was most effectively suppressed the expression of GFP-Rb (Figure 8a ). Transfection of this construct into K562 cells clearly showed that the silencing of endogenous Rb induced apoptosis, while the control lacZ si-RNA had marginal effect on the cell (Figure 8b) . Thus, the result was consistent to Abl-catalysed tyrosine phosphorylation of Rb K Nagano et al the experiments performed by using exogenously expressed Rb protein, and suggested that Rb plays a positive role in survival of Abl-dependent human tumor cells.
Discussion
Although Rb is known to be an upstream negative regulator of Abl, we demonstrate here for the first time that Rb is also a substrate of the Abl protein tyrosine kinase and may thus constitute a downstream effector of Abl. Abl and its downstream effectors are necessary for survival of CML cells, and a specific inhibitor of Abl has been used as an anticancer drug that induces apoptosis in CML cells (Druker et al., 2001; Calabretta and Perrotti, 2004; Harata et al., 2004) . A number of cytoplasmic signal transduction pathways that are normally controlled by receptor tyrosine kinases are activated by Abl; however, most of the studies have been performed by forced expression of Bcr/Abl in established cell lines or mouse models, and may not entirely apply to human tumor cells (Druker et al., 2001; Calabretta and Perrotti, 2004) . We demonstrate here that endogenous Rb is constitutively phosphorylated at tyrosine in Bcr/Abl-positive human tumor cell lines and serves as a survival factor in those cells. This raises the possibility that tyrosine-phosphorylated Rb could be a molecular target for cell-type-specific cancer therapy aimed at inducing apoptosis in Abl-dependent tumor cells.
Our findings suggest that excess Rb induces apoptosis in Abl-dependent tumor cells by inhibiting the tyrosine kinase activity of Abl, and that Abl-catalysed phosphorylation of Rb at Y805 is necessary for survival of Abl-dependent tumor cells. Our results also imply that, besides Rb, there are additional downstream targets of Abl tyrosine kinase required for survival of Abldependent tumor cells, because the replacement of Tyr-805 by Phe in Rb did not suppress the W118K-induced apoptosis completely and, likewise, the replacement of Tyr-805 by Asp reduced apoptosis only to a partial extent (Figure 7 ). Since it has been reported that Rb binds to the catalytic domain of Abl (Wang, 2000) , it is likely that excess Rb competes with additional downstream targets of Abl required for survival of Abldependent tumor cells.
Previous reports showed that expression of Rb in Rb-negative prostate cancer cells sensitized the cells to apoptosis (Bowen et al., 2002) , and that phosphorylation of Rb at S567 triggered apoptosis in tumor cells (Ma et al., 2003) . However, these results are somewhat contradictory to the observation that RbÀ/À mice die with widespread apoptosis during embryogenesis, and restoration of the caspase-resistant mutant of Rb in RbÀ/À cells or mice protects against apoptosis in a signal-and tissue-dependent manner (Harbour and Dean, 2000; Chau et al., 2002) . We do not yet have an explanation for the apparently different roles of Rb in apoptosis; however, they may result from multiple forms of Rb that arise via post-translational modification, such as site-specific phosphorylation, which may vary in different tumor cell types.
We note that the site of Abl-catalysed phosphorylation, Y805, is located in the C-terminal domain of Rb, which regulates protein-protein interactions. Rb function is regulated by site-specific phosphorylation at serine/threonine in the C-terminal domain (Knudsen and Wang, 1997; Harbour et al., 1999) , and phosphorylation of the C-terminal domain by cyclin-dependent kinase 4/6 initiates intramolecular interactions between the C-terminal domain and the B domain of Rb, resulting in dissociation of E2F (Knudsen and Wang, 1997; Harbour et al., 1999) . Recent studies also show that Rb function is regulated by acetylation at lysine in the C-terminal domain during differentiation of monocytes and muscle cells (Chan et al., 2001; Nguyen et al., 2004) . We propose that tyrosine phosphorylation of the C-terminal domain is an additional mechanism by which Rb function is regulated, thereby potentially altering the interaction of Rb with other proteins, leading to tumorigenesis. Since Rb binds numerous proteins and forms large protein complexes (Weinberg, 1995; Sherr, 1996; Harbour and Dean, 2000) , it is possible that tyrosine phosphorylation induces a conformational change in Rb that modifies the protein-protein interactions, thereby enabling Rb to express its function in survival of tumor cells. Although a direct link between tyrosine-phosphorylated Rb and the survival pathway in tumor cells remains to be elucidated, our results imply that post-translational modification of Rb may serve as a mechanism to determine cell fate (i.e., serine/threonine phosphorylation for growth, lysine acetylation for differentiation, and tyrosine phosphorylation for inhibition of apoptosis). Dysregulation of Rb may thus result in an undesirable cell fate decision that leads to tumorigenesis. More detailed proteomic analyses of the spatiotemporal regulation of protein interactions involving Rb and its dynamic changes by post-translational modifications will clarify our understanding of the regulation of cell fate and the mechanisms of tumorigenesis.
Materials and methods
Cell culture
HeLa S3 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). MCF-7 (JCRB0134), A549 (JCRB0076), KU812 (JCRB0104), and K562 (JCRB0019) cells were obtained from the Japan Health Sciences Foundation (Osaka, Japan). HeLa S3 cells were maintained in Joklik's modified minimum essential medium (MEM) (JRH Biosciences, Lenexa, KS, USA) supplemented with 10% FCS. 293-T cells were grown in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS. KU812 and K562 cells were maintained in RPMI1640 (Sigma-Aldrich, Inc., St Louis, MO, USA) supplemented with 10% FCS. A549 was maintained in MEM a (Invitrogen) supplemented with 10% FCS. MCF-7 was maintained in MEM a supplemented with 10% FCS and 10 mg/ml insulin.
Plasmids
Full-length Rb was generated from total RNA of HeLa S3 cells by RT-PCR and subcloned into pGEX4T-1 (Amersham Biosciences, Piscataway, NJ, USA), pGFP-C1 (BD Biosciences, San Jose, CA, USA), or a Flag-tagged vector, pCMV-Tag 3 (Stratagene, La Jolla, CA, USA). The entire coding region of Rb was proved to have no mutations in the nucleotide sequence. Site-directed mutagenesis was performed with Gene Tailor Site-Directed Mutagenesis System (Invitrogen) according to the manufacturer's protocol. Abl constructs were kindly provided by Drs T Shishido (Nara Institute of Science and Technology, Nara, Japan) and D Baltimore (Shishido et al., 2000) (California Institute of Technology, Pasadena, CA, USA).
Immunoprecipitation and immunoblotting
For immunoprecipitation, cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, protease inhibitor cocktail (Roche, Basel, Switzerland), 1 mM sodium orthovanadate, and the lysate was incubated with antimouse IgG, anti-Rb (IF8) conjugated to agarose (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-phosphotyrosine (PY20) (BD Biosciences), and anti-Flag M2 (SigmaAldrich Inc.) mouse monoclonal antibodies for 1 h or overnight, followed by incubation with protein A-or G-agarose (Pierce, Rockford, IL, USA) for 1 h at 41C. After extensive washes with lysis buffer, immunoprecipitates were eluted with 0.2 M glycine (pH 2.5) or SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 5% b-mercaptoethanol) and resolved by SDS-PAGE, followed by immunoblotting with anti-Rb (G3-245) (BD Biosciences), anti-phosphotyrosine (4G10) (Upstate Biotechnology, Lake Placid, NY, USA) mouse monoclonal antibodies, or anti-Abl rabbit polyclonal antibody (K-12) (Santa Cruz Biotechnology Inc.). Proteins were visualized with ECL Western Blotting Detection reagents (Amersham Biosciences).
In-gel digestion and MS analysis
In-gel tryptic digests of protein bands were performed with the Montage In-Gel Digest kit (Millipore, Bedford, MA, USA) according to the manufacturer's protocol. The peptide mixture was then analysed by tandem MS on an electrospray ionization quadruple time-of-flight mass spectrometer (Q-TOF2, Micromass, Manchester, UK) equipped with nano-flow liquid chromatography as described previously (Taoka et al., 2003) . All spectra were analysed with Mascot software (Matrix Science, London, UK) to search the nonredundant protein database compiled by the National Center for Biotechnology Information.
In vitro kinase assay The in vitro kinase assay was performed as described previously (Lewis et al., 1996) . Briefly, 293-T cells were grown on a 10-cm dish and transfected with Abl constructs. A day after transfection, cells were harvested and the lysates were immunoprecipitated with anti-Abl (K-12). The immunoprecipitates were washed and resuspended in kinase buffer (10 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , 1 mM DTT) containing GSTRb-C. Kinase reactions were initiated by adding 10 mM unlabeled ATP and 1 mCi of [g-32 P]ATP. After incubating 30 min at room temperature, reactions were stopped by adding SDS sample buffer. Proteins were then separated by SDS-PAGE, followed by Coomassie brilliant blue (CBB) staining with SimplyBlue Safe Stain (Invitrogen) or direct autoradiography.
Transfection, immunofluorescence staining, and assessment of apoptotic cells Cells were transfected transiently with Lipofectamine Plus, DMRIE-C reagents, or a Calcium Phosphate Transfection kit (Invitrogen) according to the manufacturer's protocols. For immunofluorescence staining, cells were grown on coverslips in six-well plates and fixed by adding formaldehyde (3.7% final concentration) to the medium. Fixed cells were then permeabilized with PBS containing 0.2% Triton X-100, followed by incubation in blocking solution (PBS with 1% BSA and 1% FCS) for 30 min at room temperature. Cells were washed and then incubated with anti-cytochrome c (6H2.B4) (BD Biosciences), anti-Rb (G3-245) mouse monoclonal antibodies, or anti-Abl rabbit polyclonal antibody (K-12) for 1 h, followed by incubation with secondary antibodies conjugated to fluorescein or rhodamine and visualized with a Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA, USA). Apoptotic cells were assessed by staining with 2 mg/ml Hoechst 33342 (Molecular Probes, Eugene, OR, USA), and the proportions of apoptotic nuclei were determined by scoring at least 100 GFPpositive cells with nuclei stained with Hoechst 33342 for apoptotic features. The TUNEL assay was performed using the In Situ Cell Death Detection kit (Roche) according to the manufacturer's protocol.
Generation of phospho-Rb (Y805)-specific antibody
The antibody was raised in rabbits against a synthetic phosphopeptide antigen PGGNIY*ISPLKC, where Y* represents phosphotyrosine (Sigma Genosys, Hokkaido, Japan). The phosphopeptide-reactive antiserum was first purified by affinity chromatography on a phosphopeptide-bound Sepharose, and further purified by passing the antibody through a Sepharose column bound with the nonphosphopeptide.
RNA interference
Silencing of Rb was performed with BLOCK-iT Dicer RNAi kit (Invitrogen) according to the manufacturer's protocol. The nucleotide fragments encoding N-terminal (nucleotides 456-1275: 820 bp), A/B (nucleotides 1252-1809: 558 bp), and Cterminal domains (nucleotides 2201-2938: 738 bp) of Rb were amplified by PCR, and the linear sense and antisense DNA templates of PCR products were subjected to in vitro transcription to generate single-stranded RNA (ssRNA). ssRNA was then annealed to generate double-stranded RNA (dsRNA), followed by dicing reaction. Diced siRNAs generated from N-terminal, A/B, and C-terminal domain of Rb (designated as si-Rb-N, si-Rb-AB, and si-Rb-C, respectively) and a diced control lacZ si-RNA were transfected with Lipofectamine 2000 (Invitrogen) into K562 cells according to the manufacturer's protocol. At 2 days after transfection, the cells were stained with anti-Rb and Hoechst 33342.
